Pembrolizumab for Head and Neck Cancer

Phase-Based Progress Estimates
Medical University of South Carolina, Charleston, SCHead and Neck CancerPembrolizumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer treatment combining two existing therapies in the hopes of creating a more favorable immunologic response in patients with a specific type of head and neck cancer.

Eligible Conditions
  • Head and Neck Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 12 weeks

12 weeks
Effect of Pembro + antiplatelet on major cellular parameters
Effect of Pembro + antiplatelets on immunologic markers
Frequency of adverse events reported
Tumor response rate

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Group 1
1 of 2
Group 2
1 of 2

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 1

Group 1Experimental Group · 3 Interventions: Pembrolizumab, acetylsalicylic acid, Clopidogrel · Intervention Types: Drug, Drug, Drug
Group 2Experimental Group · 3 Interventions: Pembrolizumab, acetylsalicylic acid, Clopidogrel · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
Acetylsalicylic acid
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
853 Previous Clinical Trials
5,390,146 Total Patients Enrolled
8 Trials studying Head and Neck Cancer
610 Patients Enrolled for Head and Neck Cancer
John Kaczmar, MDPrincipal InvestigatorMedical University of South Carolina

Eligibility Criteria

Age 18+ · All Participants · 12 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
A group of medical professionals reviewed your scans to see if your tumor is involved.
You are expected to live for at least 3 more months.

Frequently Asked Questions

What potential harms may arise from Pembrolizumab usage?

"The low amount of available data on pembrolizumab's efficacy and safety resulted in a score of 1 being assigned to the drug." - Anonymous Online Contributor

Unverified Answer

How many human participants are being observed for this clinical investigation?

"Affirmative, the available data on reveals that this research endeavor is currently recruiting participants. Initially posted on October 20th 2017, it seeks to enrol 20 patients from a single location." - Anonymous Online Contributor

Unverified Answer

Has this research project started accepting participants yet?

"This clinical trial, which was published in October 2017, is still actively seeking participants. The details have been recently updated on March 31st 2022 according to the information provided by" - Anonymous Online Contributor

Unverified Answer

What evidence exists to support the efficacy of Pembrolizumab?

"Presently, 1151 trials are conducted regarding the effectiveness of Pembrolizumab. Out those active studies, 175 have moved past Phase 2 and into the third phase of investigation. These medical experiments can be found across 39737 different locations globally with a concentration in Cleveland, Ohio." - Anonymous Online Contributor

Unverified Answer

What medical applications commonly utilize Pembrolizumab?

"As a therapeutic option, pembrolizumab can be used to address bursitis as well as other ailments such as melanoma, metastatic cutaneous squamous cell carcinoma, and cardiovascular disorders." - Anonymous Online Contributor

Unverified Answer

Is this research an unprecedented discovery?

"To date, 1151 clinical trials concerning the effectiveness of pembrolizumab are active across 3313 cities and 75 nations. Abbott first initiated an experiment with 15480 participants in 2005, leading to its Phase 4 drug approval stage; yet since then 982 more studies have been completed." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.